Skip to main navigation

Mobia Medical Announces Pricing of Initial Public Offering. Learn More.

Meet Mobia Medical
Vivistim Therapy
Patient Impact
Contact Us
Investors

Mobia Medical Announces Pricing of Initial Public Offering. Learn More.

Contact Us

Meet Mobia Medical
Vivistim Therapy
Patient Impact
Contact Us
Investors

Privacy Policy
Compliance
Patents

SEC Filing Details

Document Details

Form

SCHEDULE 13G

Filing Date

May 18, 2026

Document Date

May 18, 2026

Form Description

SCHEDULE 13G - Description

Filing Group

Other

Company

Mobia Medical

Issuer

MOBIA MEDICAL, INC.

Filing Formats

View HTML

Financial Information

Mobile sidebar dropdown

SEC Filings

Investor Contact

Louisa Smith
Gilmartin Group, LLC
investors@mobia.com

Subscribe to our email alerts

Email Address

Meet Mobia

Our Mission
Our Leadership
Our Culture
Our Careers

Vivistim Therapy

Our Therapy
MRI & Safety Info
Visit Vivistim.com

Patient Impact

Contact Us

Investors

The Vivistim® Paired VNS™ System (Vivistim) is intended to be used to stimulate the vagus nerve during rehabilitation therapy in order to reduce upper extremity motor deficits and improve motor function in chronic ischemic stroke patients with moderate to severe arm impairment. Do not use if you have had a bilateral or left cervical vagotomy. Risks may include, but are not limited to pain after surgery, hoarseness, bruising, swelling, coughing and throat irritation. While not observed with Vivistim, infection is a risk associated with surgery. For full safety information, please see www.vivistim.com/safety. Individual results may vary.

© 2026 Mobia Medical. All rights reserved. Serenity, Vivistim, Paired VNS, and the Mobia Medical logo are trademarks of Mobia Medical.

Privacy Policy
Compliance
Patents